PMID- 33481663
OWN - NLM
STAT- MEDLINE
DCOM- 20210226
LR  - 20210226
IS  - 1557-7430 (Electronic)
IS  - 1044-5498 (Linking)
VI  - 40
IP  - 2
DP  - 2021 Feb
TI  - Development and Validation of Epigenetic Signature Predict Survival for Patients 
      with Laryngeal Squamous Cell Carcinoma.
PG  - 247-264
LID - 10.1089/dna.2020.5789 [doi]
AB  - Establishing epigenetic signature to improve the accuracy of survival prediction 
      and optimize therapeutic strategies for laryngeal squamous cell carcinoma (LSCC) 
      by a genome-wide integrated analysis of methylation and the transcriptome. LSCC 
      DNA methylation datasets and RNA sequencing datasets were acquired from the 
      Cancer Genome Atlas (TCGA). MethylMix was applied to detect DNA 
      methylation-driven genes (MDGs), which developed an epigenetic signature. The 
      predictive accuracy and clinical value of the epigenetic signature were evaluated 
      by receiver operating characteristic and decision curve analysis, and compared 
      with tumor-node-metastasis (TNM) stage system. In addition, prognostic value of 
      the epigenetic signature was validated by external Gene Expression Omnibus (GEO) 
      database. According to five MDGs of epigenetic signature, the candidate small 
      molecules for LSCC were screen out by the CMap database. A total of 88 DNA MDGs 
      were identified, five of which (MAGEB2, SUSD1, ZNF382, ZNF418, and ZNF732) were 
      chosen to construct an epigenetic signature. The epigenetic signature can 
      effectively divide patients into high-risk and low-risk group, with the area 
      under curve (AUC) of 0.8 (5-year overall survival [OS]) and AUC of 0.745 (3-year 
      OS). Stratification analysis affirmed that the epigenetic signature was still a 
      significant statistical prognostic model in subsets of patients with different 
      clinical variables. Multivariate Cox regression analysis indicated that the 
      efficacy of epigenetic signature appears independent of other clinicopathological 
      characteristics. In terms of predictive capacity and clinical usefulness, the 
      epigenetic signature was superior to traditional TNM stage. In addition, the 
      epigenetic signature was confirmed in external LSCC cohorts from GEO. Finally, 
      CMap matched the 10 most significant small molecules as promising therapeutic 
      drugs to reverse the LSCC gene expression. An epigenetic signature, with five DNA 
      MDGs, was identified and validated in LSCC patients by integrating 
      multidimensional genomic data, which may offer novel research directions and 
      prospects for individualized treatment of patients with LSCC.
FAU - Cui, Jie
AU  - Cui J
AD  - Department of Head and Neck Surgery, Affiliated Cancer Hospital & Institute of 
      Guangzhou Medical University, Guangzhou, PR China.
FAU - Wang, Liping
AU  - Wang L
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated 
      Hospital of Hainan Medical University, Haikou, PR China.
FAU - Zhong, Waisheng
AU  - Zhong W
AD  - Department of Head Neck Surgery, Hunan Cancer Hospital and The Affiliated Cancer 
      Hospital of Xiangya School of Medicine, Central South University, Changsha, PR 
      China.
FAU - Chen, Zhen
AU  - Chen Z
AD  - Department of Intensive Care Unit, Shunde Hospital, Southern Medical University 
      (The First People's Hospital of Shunde), Foshan, PR China.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Head Neck Surgery, Hunan Cancer Hospital and The Affiliated Cancer 
      Hospital of Xiangya School of Medicine, Central South University, Changsha, PR 
      China.
FAU - Yang, Hong
AU  - Yang H
AD  - Department of Head and Neck Surgery, Affiliated Cancer Hospital & Institute of 
      Guangzhou Medical University, Guangzhou, PR China.
FAU - Liu, Genglong
AU  - Liu G
AD  - Department of Pathology, Affiliated Cancer Hospital & Institute of Guangzhou 
      Medical University, Guangzhou, PR China.
LA  - eng
PT  - Journal Article
PT  - Validation Study
DEP - 20210121
PL  - United States
TA  - DNA Cell Biol
JT  - DNA and cell biology
JID - 9004522
SB  - IM
MH  - Adult
MH  - DNA Methylation
MH  - *Epigenesis, Genetic
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*diagnosis/*genetics/pathology
MH  - Male
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Squamous Cell Carcinoma of Head and Neck/*diagnosis/*genetics/pathology
MH  - Survival Analysis
OTO - NOTNLM
OT  - DNA methylation-driven genes
OT  - epigenetics
OT  - laryngeal squamous cell carcinoma
OT  - overall survival
OT  - prediction
EDAT- 2021/01/23 06:00
MHDA- 2021/02/27 06:00
CRDT- 2021/01/22 17:11
PHST- 2021/01/23 06:00 [pubmed]
PHST- 2021/02/27 06:00 [medline]
PHST- 2021/01/22 17:11 [entrez]
AID - 10.1089/dna.2020.5789 [doi]
PST - ppublish
SO  - DNA Cell Biol. 2021 Feb;40(2):247-264. doi: 10.1089/dna.2020.5789. Epub 2021 Jan 
      21.